Vistagen Brings In GATC Health’s Predictive AI as It Plans the Next Fasedienol Phase 3

Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company developing intranasal product candidates called pherines, announced on October 20, 2026 a collaboration with GATC Health, a tech-bio company that applies artificial intelligence and multiomics to drug discovery and development. Under the agreement, GATC Health brings its Operon platform and Derisq report to Vistagen’s lead clinical-stage programs.

Predictive Modeling Across Three Programs

GATC Health is providing strategic insights for Vistagen’s potential next Phase 3 study of fasedienol in social anxiety disorder, with the Liebowitz Social Anxiety Scale (LSAS) as the primary efficacy endpoint. The work also covers potential Phase 2 studies of itruvone for major depressive disorder and refisolone for menopausal hot flashes.

According to the companies, predictive modeling will complement traditional development approaches on questions that affect protocol development, pipeline prioritization and resource allocation. GATC Health’s Derisq report simulates clinical trial outcomes in silico to identify safety, efficacy and off-target outcomes before development capital is committed.

“We are incorporating key predictive insights from our collaboration with GATC Health into protocol development for our fasedienol program in social anxiety disorder, complementing our experience and existing datasets,” said Shawn Singh, President and Chief Executive Officer of Vistagen. Jayson Uffens, Co-Founder and Chief Technology Officer of GATC Health, said Derisq “gives the team a second signal to test their thinking against as they plan the next studies.”

Why the Next Fasedienol Trial Has a New Endpoint

The collaboration follows several months of new fasedienol data. In June, Vistagen reported that PALISADE-4 did not achieve its primary endpoint in the overall trial population (n=238). That Phase 3 trial measured anxiety during a simulated public speaking challenge using the Subjective Units of Distress Scale (SUDS). In a post-hoc analysis of 123 patients with very severe social anxiety, defined as a baseline LSAS score of 95 or higher, fasedienol showed a nominally statistically significant difference of -9.1 points versus placebo (p=0.036).

Based on the totality of its data, Vistagen said it plans to meet with the FDA to discuss a registrational pathway potentially supported by a single future multi-dose Phase 3 trial with the LSAS as the primary endpoint. The company cited confirmatory evidence from its positive PALISADE-2 Phase 3 trial and other placebo-controlled studies.

Data since then has focused on repeat and long-term use. An exploratory Phase 2 repeat dose study (N=61) showed numerical separation from placebo in both active arms, although the differences were not statistically significant. In September, Vistagen reported preliminary open-label extension data from PALISADE-4, in which as-needed fasedienol use for up to 12 months (N=322) was well tolerated with no new drug-related safety findings. Vistagen also presented very severe subgroup findings at Psych Congress 2026.

Resource Allocation and the Cash Runway

Resource allocation is one of the areas the GATC Health work is designed to inform. Vistagen reported cash, cash equivalents and marketable securities of $31.7 million as of June 30, 2026, and net loss narrowed to $13.0 million for the quarter from $15.1 million a year earlier.

The company said its cash should fund operations into 2027 but is not expected to extend its runway for more than a year. “Since reporting PALISADE-4 results in June, we have moved swiftly to define next steps for fasedienol, evaluate strategic options, and preserve cash,” Singh said in August, adding that Vistagen looked forward to meeting with the FDA in the near term.

Strategic Investment Summary

• Collaboration Announced: Vistagen (NASDAQ: VTGN) announced on October 20, 2026 a collaboration with GATC Health to apply the Operon platform and Derisq report to its lead clinical-stage programs.
• Fasedienol Protocol: Vistagen is incorporating predictive insights into protocol development for a potential next Phase 3 study of fasedienol in social anxiety disorder, with the LSAS as the primary endpoint.
• Broader Pipeline: The collaboration also covers potential Phase 2 studies of itruvone for major depressive disorder and refisolone for menopausal hot flashes.
• PALISADE-4 Context: The Phase 3 trial missed its primary endpoint overall, while a post-hoc very severe subgroup (n=123) showed a nominally significant difference versus placebo (p=0.036).
• Long-Term Safety: Preliminary open-label extension data showed as-needed fasedienol use for up to 12 months (N=322) was well tolerated with no new drug-related safety findings.
• Cash Position: Cash, cash equivalents and marketable securities totaled $31.7 million as of June 30, 2026, expected to fund operations into 2027.

Find out more about the latest corporate developments and financial reports at the Vistagen investor portal.